Diffuse intrinsic pontine glioma, also referred to as DIPG, diffuse midline glioma, or infiltrative brainstem glioma, is described in the packet as a neuroglial tumor arising from the middle portion of the brain stem. According to the packet definition, it usually affects children and has a poor prognosis. The packet lists one subtype, diffuse midline glioma, H3 K27-altered.

The packet does not certify clinical features, frequencies, or age-of-onset categories for this condition. The only descriptive statement available is that the tumor usually affects children.

The packet lists no associated genes and no inheritance pattern for diffuse intrinsic pontine glioma, so the genetic basis is not certified here. The definition describes the tumor as arising from the middle portion of the brain stem.

Specific diagnostic tests or criteria are not certified in this packet.

Treatment coverage is not certified in this packet, and no foundational therapies or FDA-approved treatments are recorded. Two investigational agents hold orphan drug designation for diffuse midline glioma or diffuse intrinsic pontine glioma. Designation is a regulatory status and does not indicate approval, development stage, or availability.

The packet definition states that the condition has a poor prognosis. No natural history, survival, or outcome data are certified in this packet.

According to ClinicalTrials.gov records in the packet, a number of active clinical trials exist for this condition, with some recruiting and others not yet recruiting. Interventions include drug therapy, biologic therapy, and procedural interventions, and gene or cell therapy trials appear among them, along with a registry and repository study. Active clinical trials for this condition are listed on ClinicalTrials.gov.